10.3389/fphar.2018.00700.s001 Chiyuan Ma Chiyuan Ma Xiaopeng Zhou Xiaopeng Zhou Kai Xu Kai Xu Linyan Wang Linyan Wang Yute Yang Yute Yang Wei Wang Wei Wang An Liu An Liu Jisheng Ran Jisheng Ran Shigui Yan Shigui Yan Haobo Wu Haobo Wu Lidong Wu Lidong Wu Data_Sheet_1_Specnuezhenide Decreases Interleukin-1β-Induced Inflammation in Rat Chondrocytes and Reduces Joint Destruction in Osteoarthritic Rats.DOCX Frontiers 2018 specnuezhenide osteoarthritis chondrocyte NF-κB wnt/β-catenin 2018-06-28 14:06:51 Dataset https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Specnuezhenide_Decreases_Interleukin-1_-Induced_Inflammation_in_Rat_Chondrocytes_and_Reduces_Joint_Destruction_in_Osteoarthritic_Rats_DOCX/6715649 <p>As a chronic disease, osteoarthritis (OA) leads to the degradation of both cartilage and subchondral bone, its development being mediated by proinflammatory cytokines like interleukin-1β. In the present study, the anti-inflammatory effect of specnuezhenide (SPN) in OA and its underlying mechanism were studied in vitro and in vivo. The results showed that SPN decreases the expression of cartilage matrix-degrading enzymes and the activation of NF-κB and wnt/β-catenin signaling, and increases chondrocyte-specific gene expression in IL-1β-induced inflammation in chondrocytes. Furthermore, SPN treatment prevents the degeneration of both cartilage and subchondral bone in a rat model of OA. To the best of our knowledge, this study is the first to report that SPN decreases interleukin-1β-induced inflammation in rat chondrocytes by inhibiting the activation of the NF-κB and wnt/β-catenin pathways, and, thus, has therapeutic potential in the treatment of OA.</p>